|Last||Chg. %||Chg. Abs.||ISIN||Date, Time||MPQ|
Information Dissemination System1
Mr. Franck Grimaud, President & CBO
Mr. David Lawrence, CFO
Mr. Wolfgang Bender, CMO
Mr. Frederic Jacotot, General Counsel
Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC.
The Company has proprietary vaccines in development including a unique vaccine against Lyme disease.
Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with over 450 employees.
More information is available at www.valneva.com.
|02/21/2019||Consolidated financial statements (unaudited)|
|03/21/2019||Consolidated & Statutory financial statements (audited)|
|05/02/2019||Interim results 1st quarter 2019|
|06/24/2019||Record date "Annual General Meeting" (according to French corporate law)|
|06/27/2019||Annual General Meeting|
|07/08/2019||Record date "dividends"|
|07/09/2019||Dividend payment date|
|08/01/2019||Results for the 1st half year 2019|
|10/31/2019||Interim results 1st - 3rd quarter 2019|
Source: provided by the company
Record date "Dividends": Date on which settled positions are struck in the books of the Issuer`s CSD at close of business to determine the entitlement to dividends. Origination of entitlement is still linked to the Ex-dividend date.
Record date "Annual General Meeting": Date for participation to Annual General Meeting.